1. Du, Hongzhi, Pang, Mao, Hou, Xiaoying, Yuan, Shengtao, Sun, Li. 2017. PLOD2 in cancer research. In Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 90, 670-676. doi:10.1016/j.biopha.2017.04.023. https://pubmed.ncbi.nlm.nih.gov/28415047/
2. Wang, Zhen, Fan, Gentao, Zhu, Hao, Zhao, Jianning, Zhou, Guangxin. 2022. PLOD2 high expression associates with immune infiltration and facilitates cancer progression in osteosarcoma. In Frontiers in oncology, 12, 980390. doi:10.3389/fonc.2022.980390. https://pubmed.ncbi.nlm.nih.gov/36276118/
3. Liu, Tao, Xiang, Wan, Chen, Zhizhuang, Luo, Yongwen, Chen, Liang. 2023. Hypoxia-induced PLOD2 promotes clear cell renal cell carcinoma progression via modulating EGFR-dependent AKT pathway activation. In Cell death & disease, 14, 774. doi:10.1038/s41419-023-06298-7. https://pubmed.ncbi.nlm.nih.gov/38008826/
4. Li, Huan, Zhao, Jun, Deng, Hao, Liu, Honghai, Zhang, Xinzong. 2023. N6-methyladenosine modification of PLOD2 causes spermatocyte damage in rats with varicocele. In Cellular & molecular biology letters, 28, 72. doi:10.1186/s11658-023-00475-4. https://pubmed.ncbi.nlm.nih.gov/37670228/
5. Chen, Yimeng, He, Yichen, Li, Zhengsheng, He, Xiaozhou, Xue, Dong. 2024. METTL3 facilitates renal cell carcinoma progression by PLOD2 m6A-methylation under prolonged hypoxia. In Cell death & disease, 15, 62. doi:10.1038/s41419-023-06411-w. https://pubmed.ncbi.nlm.nih.gov/38233403/
6. Lan, Jiawen, Zhang, Sijing, Zheng, Lin, Zhou, Miao, Zhou, Jun. 2023. PLOD2 promotes colorectal cancer progression by stabilizing USP15 to activate the AKT/mTOR signaling pathway. In Cancer science, 114, 3190-3202. doi:10.1111/cas.15851. https://pubmed.ncbi.nlm.nih.gov/37227305/
智鼠故事 
